Navicixizumab - Celgene Corporation/OncoMed Pharmaceuticals

Drug Profile

Navicixizumab - Celgene Corporation/OncoMed Pharmaceuticals

Alternative Names: Anti-DLL4/VEGF bispecific; Anti-DLL4/VEGF bispecific antibody; Navicixizumab; OMP 305B83

Latest Information Update: 28 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator OncoMed Pharmaceuticals
  • Class Antineoplastics; Bispecific antibodies; Monoclonal antibodies
  • Mechanism of Action DLL4 protein inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Colorectal cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • No development reported Solid tumours

Most Recent Events

  • 28 Jan 2018 No recent reports of development identified for phase-I development in Solid-tumours(Second-line therapy or greater) in USA (IV, Infusion)
  • 20 Jan 2017 Phase-I clinical trials in Fallopian tube cancer (Combination therapy, Second-line therapy or greater) in USA (IV) (NCT03030287)
  • 20 Jan 2017 Phase-I clinical trials in Ovarian cancer (Combination therapy; Second-line therapy or greater) in USA (IV) (NCT03030287)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top